Uniqure NV QURE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:31 PM EDT
5.26quote price arrow down-0.15 (-2.77%)
Volume
228,897
52 week range
4.76 - 22.48
Loading...
  • Open5.35
  • Day High5.40
  • Day Low5.26
  • Prev Close5.41
  • 52 Week High22.48
  • 52 Week High Date05/11/23
  • 52 Week Low4.76
  • 52 Week Low Date03/15/24

Key Stats

  • Market Cap251.644M
  • Shares Out47.84M
  • 10 Day Average Volume1.34M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change-21.86

KEY STATS

  • Open5.35
  • Day High5.40
  • Day Low5.26
  • Prev Close5.41
  • 52 Week High22.48
  • 52 Week High Date05/11/23
  • 52 Week Low4.76
  • 52 Week Low Date03/15/24
  • Market Cap251.644M
  • Shares Out47.84M
  • 10 Day Average Volume1.34M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change-21.86

RATIOS/PROFITABILITY

  • EPS (TTM)-6.47
  • P/E (TTM)-0.81
  • Fwd P/E (NTM)-1.01
  • EBITDA (TTM)-270.971M
  • ROE (TTM)-90.24%
  • Revenue (TTM)15.843M
  • Gross Margin (TTM)13.98%
  • Net Margin (TTM)-1,947.09%
  • Debt To Equity (MRQ)238.84%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Uniqure NV

 

Profile

MORE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing...
David Meek
Non-Executive Independent Chairman of the Board
Matthew Kapusta CPA
Chief Executive Officer, Executive Director
Pierre Caloz
Chief Operations Officer
Christian Klemt CPA
Chief Financial Officer
Address
Paasheuvelweg 25a
Amsterdam
1105 BP
Netherlands